Outcomes of patients with ER+/HER2+non-metastatic breast cancer treated with trastuzumab without chemotherapy

被引：0
|
作者：
Nguy, Susanna [1 ]
Wu, S. Peter [1 ]
Oh, Cheongeun [1 ]
Gerber, Naamit K. [1 ]
机构：
[1] NYU Langone Med Ctr, New York, NY USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P1-18-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-18-02
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy
    Luc Cabel
    Dan Rosenblum
    Florence Lerebours
    Etienne Brain
    Delphine Loirat
    Mattias Bergqvist
    Paul Cottu
    Anne Donnadieu
    Anne Bethune
    Nicolas Kiavue
    Manuel Rodrigues
    Jean-Yves Pierga
    Marie-Laure Tanguy
    François-Clément Bidard
    Breast Cancer Research, 22
  • [32] A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer
    Macpherson, Iain R.
    Spiliopoulou, Pavlina
    Rafii, Saeed
    Saggese, Matilde
    Baird, Richard D.
    Garcia-Corbacho, Javier
    Italiano, Antoine
    Bonneterre, Jacques
    Campone, Mario
    Cresti, Nicola
    Posner, John
    Takeda, Yousuke
    Arimura, Akinori
    Spicer, James
    BREAST CANCER RESEARCH, 2019, 22 (01)
  • [33] High incidence of brain metastases in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) treated with trastuzumab and chemotherapy
    Gori, S.
    Rimondini, S.
    De Angelis, V.
    Sidoni, A.
    Mosconi, A. M.
    Aristei, C.
    Franceschi, E.
    Esposti, R. Degli
    Colozza, M.
    Crino, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 115 - 116
  • [34] A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer
    Iain R. Macpherson
    Pavlina Spiliopoulou
    Saeed Rafii
    Matilde Saggese
    Richard D. Baird
    Javier Garcia-Corbacho
    Antoine Italiano
    Jacques Bonneterre
    Mario Campone
    Nicola Cresti
    John Posner
    Yousuke Takeda
    Akinori Arimura
    James Spicer
    Breast Cancer Research, 22
  • [35] Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab
    Che, Yi-Qun
    Zhang, Yue
    Wang, Di
    Liu, Hui-Ying
    Shen, Di
    Luo, Yang
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 3727 - 3734
  • [36] ER+, HER2-advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
    Chen, Jessica W.
    Jacot, William
    Cortes, Javier
    Krop, Ian E.
    Dent, Susan
    Harbeck, Nadia
    De Laurentiis, Michelino
    Dieras, Veronique
    Im, Young-Hyuck
    Stout, Thomas J.
    Schimmoller, Frauke
    Savage, Heidi M.
    Hutchinson, Katherine E.
    Wilson, Timothy R.
    MOLECULAR ONCOLOGY, 2023, 17 (10) : 2000 - 2016
  • [37] Treatment patterns and real world clinical outcomes in ER+/HER2-post-menopausal metastatic breast cancer patients in the United States
    Zanotti, Giovanni
    Hunger, Matthias
    Perkins, Julia J.
    Horblyuk, Ruslan
    Martin, Monique
    BMC CANCER, 2017, 17
  • [38] Co-Targeting ER and FGFR in patients with ER+/HER2-FGFR amplified (amp) Metastatic Breast Cancer (MBC)
    Jhaveri, K.
    Syed, U.
    Wong, S.
    D'andrea, G.
    Lake, D.
    Goldfarb, S.
    Gajria, D.
    Ligresti, L.
    Rogado, A.
    Reis-Filho, J.
    Chandarlapaty, S.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E42 - E42
  • [39] Treatment goals and quality of life (QOL) in a survey of patients with ER+/HER2-metastatic breast cancer (mBC)
    Sammons, Sarah L.
    Meisel, Jane
    Shanahan, Kelly
    Pluard, Timothy
    Kozlowski, Monica
    Carroll, Dominic
    Attias, Elizabeth
    CANCER RESEARCH, 2023, 83 (05)
  • [40] Gene signatures as potential predictive markers of response to neoadjuvant chemotherapy in ER+/HER2+breast cancer patients
    Risi, E.
    Grilli, A.
    Migliaccio, I.
    Biagioni, C.
    Guarducci, C.
    Bonechi, M.
    McCartney, A.
    Vitale, S.
    Biganzoli, L.
    Bicciato, S.
    Di Leo, A.
    Malorni, L.
    ANNALS OF ONCOLOGY, 2017, 28
12345